Truist lowered the firm’s price target on Edwards Lifesciences to $83 from $105 and keeps a Buy rating on the shares as part of a broader research note on MedTech. The sector continues to trade down on fear of exposure to GLP-1s, and even good Q3 earnings may not matter amid a GLP-1 sector overhang, the analyst tells investors in a research note. While Truist continues to believe that the dramatic GLP1-driven sector pullback is likely overdone and that “narrative” is driving indiscriminate selling more so than a tangible fundamental impact, it’s hard to say when/if the GLP-1 overhang will subside.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EW:
- Edwards Lifesciences put volume heavy and directionally bearish
- Citi cuts Edwards Lifesciences target, opens ‘negative catalyst watch’
- Edwards Lifesciences (EW) Under the Radar of EU Antitrust Regulators
- Edwards tells Reuters cooperating with EU antitrust regulators after raid
- DraftKings upgraded, Snap initiated at Sell: Wall Street’s top analyst calls